🚀 VC round data is live in beta, check it out!
Ansell Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ansell and similar public comparables like Haemonetics, Dentsply Sirona, Inner Mongolia Furui Medical Science, Schott Pharma and more.
Ansell Overview
About Ansell
Ansell is a leading supplier of protective gloves for use in healthcare and industrial settings, earning approximately 55% of revenue and 50% of operating profit from the healthcare segment and the remainder from the industrial segment. The company holds a large number of patents, and the majority of sales come from its key branded product ranges. Ansell has a global manufacturing and distribution footprint and distributes via key partners as well as directly across more than 100 countries. In fiscal 2025, Ansell earned 46% of revenue in North America, 31% from Europe, Middle East, and Africa, 14% across Asia-Pacific, and the remaining 10% in Latin America.
Founded
1920
HQ
Employees
15.7K
Website
Sectors
Financials (LTM)
EV
$4B
Ansell Financials
Ansell reported last 12-month revenue of $2B and EBITDA of $384M.
In the same LTM period, Ansell generated $879M in gross profit, $384M in EBITDA, and $203M in net income.
Revenue (LTM)
Ansell P&L
In the most recent fiscal year, Ansell reported revenue of $2B and EBITDA of $358M.
Ansell expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $879M | XXX | $825M | XXX | XXX | XXX |
| Gross Margin | 43% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $384M | XXX | $358M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $203M | XXX | $200M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $461M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ansell Stock Performance
Ansell has current market cap of $3B, and enterprise value of $4B.
Market Cap Evolution
Ansell's stock price is $22.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $3B | -1.1% | XXX | XXX | XXX | $1.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnsell Valuation Multiples
Ansell trades at 1.9x EV/Revenue multiple, and 10.0x EV/EBITDA.
EV / Revenue (LTM)
Ansell Financial Valuation Multiples
As of March 20, 2026, Ansell has market cap of $3B and EV of $4B.
Equity research analysts estimate Ansell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ansell has a P/E ratio of 16.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.0x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 12.5x | XXX | 13.5x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | 4.7x | XXX | XXX | XXX |
| P/E | 16.1x | XXX | 16.3x | XXX | XXX | XXX |
| EV/FCF | 16.4x | XXX | 22.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ansell Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ansell Margins & Growth Rates
Ansell's revenue in the last 12 month grew by 4%.
Ansell's revenue per employee in the last FY averaged $0.1M.
Ansell's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ansell's rule of X is 28% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ansell Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 32% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ansell Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Haemonetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dentsply Sirona | XXX | XXX | XXX | XXX | XXX | XXX |
| Inner Mongolia Furui Medical Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Shandong Weigao Blood | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ansell M&A Activity
Ansell acquired XXX companies to date.
Last acquisition by Ansell was on XXXXXXXX, XXXXX. Ansell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ansell
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAnsell Investment Activity
Ansell invested in XXX companies to date.
Ansell made its latest investment on XXXXXXXX, XXXXX. Ansell invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ansell
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ansell
| When was Ansell founded? | Ansell was founded in 1920. |
| Where is Ansell headquartered? | Ansell is headquartered in Australia. |
| How many employees does Ansell have? | As of today, Ansell has over 15K employees. |
| Who is the CEO of Ansell? | Ansell's CEO is Neil I. Salmon. |
| Is Ansell publicly listed? | Yes, Ansell is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Ansell? | Ansell trades under ANN ticker. |
| When did Ansell go public? | Ansell went public in 1985. |
| Who are competitors of Ansell? | Ansell main competitors are Haemonetics, Dentsply Sirona, Inner Mongolia Furui Medical Science, Schott Pharma. |
| What is the current market cap of Ansell? | Ansell's current market cap is $3B. |
| What is the current revenue of Ansell? | Ansell's last 12 months revenue is $2B. |
| What is the current revenue growth of Ansell? | Ansell revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Ansell? | Current revenue multiple of Ansell is 1.9x. |
| Is Ansell profitable? | Yes, Ansell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ansell? | Ansell's last 12 months EBITDA is $384M. |
| What is Ansell's EBITDA margin? | Ansell's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Ansell? | Current EBITDA multiple of Ansell is 10.0x. |
| What is the current FCF of Ansell? | Ansell's last 12 months FCF is $235M. |
| What is Ansell's FCF margin? | Ansell's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Ansell? | Current FCF multiple of Ansell is 16.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.